Efficacy of reovirus therapy combined with cyclophosphamide and gene-modified cell vaccines on tumors induced in mice by HPV16-transformed cells

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 421-426

  Sobotkova, Eva ^a   Duskova, Martina ^a   Eckschlager, Tomas ^b   Vonka, Vladimir ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Cyclophosphamide; Gene modified cells; HPV16 transformed cells; Oncolytic effect; Reovirus

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CELL BASED GENE THERAPY; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; INOCULATION; MONOTHERAPY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REOVIRUS; SINGLE DRUG DOSE; TREATMENT DURATION; TUMOR; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN PAPILLOMAVIRUS 16; INTERLEUKIN-12; INTERLEUKIN-2; MAMMALIAN ORTHOREOVIRUS 3; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOLYTIC VIROTHERAPY;

EID: 48749100494     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000024     Document Type: Article

References (30)

1. Sinkovics JG and Horwath JC: Viral Therapy of Human Cancers. Marcel Dekker, New York, 2005.
2. Davis JJ and Fang B: Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 7: 1380-1389, 2005.
3. Russell SJ and Peng KW: Viruses as anticancer drugs. Trends Pharmacol Sci 28: 326-333, 2007.
4. Vähä-Koskela MJ, Heikkilä JE and Hinkkanen AE: Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216, 2007.
5. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE Jr and Dermody TS: Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. J Infect Dis 191: 1221-1224, 2005.
6. Lerner AM, Cherry JD, Klein JO and Finland M: Infections with reoviruses. N Engl J Med 267: 947-952, 1962.
7. Minuk GY, Paul RW and Lee PW: The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 16: 55-60, 1985.
8. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998.
9. Coffey MC, Strong JE, Forsyth PA and Lee PWK: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998.
10. Figova K, Hrabeta J and Eckschlager T: Reovirus-possible therapy of cancer. Neoplasma 53: 457-462, 2006.
11. Janouskova O, Sima P and Kunke D: Combined suicide gene and immunostimulatory gene therapy using AAV-mediated gene transfer to HPV-16 transformed mouse cells: decrease of oncogenicity and induction of protection. Int J Oncol 22: 569-577, 2003.
12. Indrova M, Bieblova J, Jandlova T, Vonka V, Pajtasz-Piasecka E and Reinis M: Chemotherapy, IL-2 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours. Int J Oncol 28: 253-259, 2006.
13. Yang WQ, Lun X, Palmer CA, et al: Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 10: 8561-8576, 2004.
14. Everts B and van der Poel HG: Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12:141-161, 2005.
15. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3: 639-645, 1997.
16. Heise C, Lemmon M and Kim D: Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Clin Cancer Res 6: 4908-4914, 2000.
17. Toyoizumi T, Mick R, Abbas AE, Kang EH, Kaiser LR and Molnar-Kimber KL: Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 10: 3013-3029, 1999.
18. Cinatl J Jr, Cinatl J, Michaelis M, et al: Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 63: 1508-1514, 2003.
19. Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N and Henderson DR: A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Cancer Res 61: 6428-6436, 2001.
20. Qiao J, Wang H, Kottke T, et al: Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269, 2008.
21. Bass KK and Mastrangelo MJ: Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47: 1-12, 1998.
22. Lake RA and Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5: 397-405, 2005.
23. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34: 336-344, 2004.
24. Motoyoshi Y, Kaminoda K, Saitoh O, et al: Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncol Rep 16: 141-146, 2006.
25. Ikeda K, Wakimoto H, Ichikawa T, Jhung S, Hochberg FH, Louis DN and Chiocca EA: Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J Virol 74: 4765-4775, 2000.
26. Ikeda K, Ichikawa T, Wakimoto H, et al: Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med 5: 881-887, 1999.
27. Wakimoto H, Ikeda K, Abe T, et al: The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther 5: 275-282, 2002.
28. Kambara H, Saeki Y and Chiocca EA: Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. Cancer Res 65: 11255-11258, 2005.
29. Hirasawa K, Nishikawa SG, Norman KL, et al: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353, 2003.
30. Smakman N, vander Bilt JD, van den Wollenberg DJ, Hoeben RC, Borel Rinkes IH and Kranenburg O: Immunosuppression promotes reovirus therapy of colorectal liver metastases. Cancer Gene Ther 13: 815-818, 2006.